Mini Review - Annals of Clinical Trials and Vaccines Research (2022) Volume 12, Issue 4

In Clinical Practice Hepatocellular Carcinoma.

Xian Sun*

Department of Breast Disease, Cancer Hospital of Zhengzhou University, China

*Corresponding Author:
Xian Sun Department of Breast Disease, Cancer Hospital of Zhengzhou University, ChinaTel: +867896542301E-mail:

Received: 02-Aug-2022, Manuscript No. ACTVR-22-71815 Editor assigned: 05-Aug-2022, PreQC No. ACTVR-22-71815(PQ); Reviewed: 16-Aug-2022, QC No. ACTVR-22-71815; Revised: 23-Aug-2022, Manuscript No. ACTVR-22-71815(R); Published: 31- Aug-2022, DOI: 10.37532/actvr.2022.12(4).66-69


Depending on the extent of the disease, the function of the liver, and the patient’s fitness, several treatment approaches are needed for patients with hepatocellular carcinoma (HCC). In clinical practise, we assessed the multidisciplinary management of HCC. One of the most prevalent diseases in the world and the third leading cause of cancer-related death is hepatocellular carcinoma (HCC). It is challenging to diagnose and treat HCC at an early stage since the mechanisms behind its aetiology are poorly understood. By base pairing with the translated regions (UTRs) of their target messenger RNAs, microRNAs (miRNAs), a type of noncoding single-stranded RNAs of nucleotides in length, posttranscriptionally regulate gene expression (mRNAs). Many malignancies, if not all of them, exhibit aberrant miRNA expression, and numerous unregulated miRNAs have been shown to play critical roles in the development and spread of cancer by controlling the expression of various oncogenes or tumour suppressor genes. We will describe the rules and purposes of miRNAs that are abnormally expressed in HCC in this paper. We will also talk about the possible use of miRNAs as diagnostic and prognostic biomarkers of HCC, as well as their prospective roles in the treatment of HCC.

A qualitative research design was used for this secondary content analysis. Adults with neuromuscular disorder-related spasticity were invited to take part in the acute inpatient rehabilitation programme. They were requested to participate in a semi-structured interview to explain and characterise the type of spasticity they regularly experienced. Daily life activities, function, and mobility are all impacted by spasticity. Pain, immobility, and a higher risk of falling can result from untreated spasticity. There were opportunities lost to provide patients with spasticity with the proper care. The strategies for bedside care mentioned by patients with spasticity are described. To better control spasticity, complementary therapies should be used in addition to medicine. Spasticity reports from patients are significant and ought to be considered in clinical assessment and management.


clinical practice • carcinomacancertumor • oncogene

Abbreviations: HCC: Hepatocellular carcinoma • TCM: Traditional Chinese Medicine • NMF: Nonnegative matrix factorization • LSSVM: Least squares support vector machines • KNN: K-nearest neighbor • NAFLD: Non-Alcoholic Fatty Liver Disease


Only 10–20% of individuals with hepatocellular carcinoma (HCC), a highly aggressive illness, are candidates for curative surgery. In 30–40% of patients in Western nations, the disease is discovered in its early stages and is treatable with potentially curative procedures such surgical resection, liver transplantation, and loco regional radiofrequency ablation. Treatment options vary on the stage [1]. In some patients, a five-year survival rate of between 60 and 70 percent is possible. Coexisting severe cirrhosis, a sizable initial lesion, multifocal disease, invasion and thrombosis of significant blood arteries, a depleted liver reserve, and further hepatic metastases are causes of tumour unrepeatability. Due to the underlying liver disease and the absence of efficient treatment alternatives, the prognosis is poor for diseases that are detected at an advanced stage or that continue to progress following loco regional therapy [2]. There are unrespectable tumours in about 80% of cases, and the prognosis is very bad; the median survival time is only 4 months. Loco-regional and systemic therapies may be used to treat unrespectable HCC. In randomised investigations, Tran’s arterial chemoembolization has been shown to improve survival in a small subset of patients. Therefore, the finest supportive care and systemic chemotherapy continue to be the main options for palliative treatment for the majority of HCC patients with unrespectable tumours [3].

The third leading cause of cancer-related death worldwide and the sixth most prevalent malignant disease is hepatocellular carcinoma (HCC). Numerous illnesses, including viral hepatitis, alcoholic hepatitis, non-alcoholic fatty liver disease (NAFLD), metabolic syndrome, and diabetes mellitus have been linked to the aetiology of HCC. De novo HCC is brought on by chronic hepatitis and liver cirrhosis sequences.

HCC is seen as having a higher potential for metastatic spread, malignant transformation, and invasiveness. As a result, choosing the best disease management is challenging. Clinical therapy of HCC involves a range of therapeutic options depending on the extent of the disease, the Child-Pugh class of the liver, and the patients’ fitness (age, performance status (PS), and comorbidities). In order to adapt first line medical treatment with sorafenib in the advanced stage, a decision-making procedure that takes nutritional, functional, and comorbidity status into account is necessary. The main therapeutic difficulty is selecting appropriate, personalised therapy based on prognostic variables and by balancing projected toxicity and efficacy. Elderly HCC patients are common. Elderly status (age > 65), PS > 2, and/or comorbidities are significant factors that determine toxicities and restrict patients’ quality of life after treatment, hence restricting the indication of sorafenib [4].

Patients with type 2 diabetes who received a sitagliptin prescription from the teaching hospital during the trial period were included. The hospital must have supplied these individuals with sitagliptin more than once, and data extraction must be possible from their medical records. Patients who were taking other DPP-4 inhibitors before starting sitagliptin, patients who were prescribed sitagliptin as a first-line medication, and patients who were not started on sitagliptin by the teaching hospital under study were excluded from the study because their prior data would not have been available for comparison [5].

According to the existing clinical data, men seem to develop chronic hepatitis C more quickly than women do, and men and postmenopausal women are more likely to develop cirrhosis. Menopausal women with chronic hepatitis C virus infection had a higher percentage of women with advanced fibrosis (cirrhosis). Cirrhosis frequently coexists with HCC, making it a potential precursor to cancer. In fact, cirrhosis is present in the majority of HCC patients globally. Cirrhosis, which is present in 80%– 90% of individuals with HCC, is promoted by both HBV and HCV [6]. Depending on the aetiology, area or ethnicity, and stage of cirrhosis, people with cirrhosis have a 5-year cumulative risk of acquiring HCC that ranges between 5% and 30%. It’s interesting to note that cirrhotic individuals with HCC have much lower testosterone, dihydrotestosterone, and dehydroepiandrosterone plasma concentrations than cirrhotic patients without HCC. Male HCC patients have been shown to have low testosterone levels and cirrhotic individuals to have high progesterone levels. It is debatable if premalignant cirrhosis and elevated progesterone levels are related. The development of HCC results from greater progesterone level. It should be highlighted that the age of natural menopause and the risk of HCC were inversely correlated. Indicating that at least female sex hormones like progesterone or oestrogen may be protective against HCC are the finding that oophorectomy performed at age 50 or younger during premenopausal years was a risk factor for the disease [7].

Materials and Methods

We chose patients at random from our clinical practise who had hair or scalp problems and for whom trichoscopy played a key role in elucidating the diagnosis, differential diagnosis, and prognosis and/or in tracking the therapeutic response. When accessible, the trichoscopic features were matched to information from the literature [8].

Patients with HCC were assessed by a multidisciplinary disease management team and given medicinal, local, regional, and/ or surgical treatments in clinical settings. These treatments were selected among those that were indicated and authorised for HCC treatment at various stages. Because patients were treated according to accepted clinical practise and without the need for any extra medical intervention, it was not a clinical study and no permission from the institutional review board or ethical committee was required [9].

When liver resection was an option, it was used to treat HCC patients based on the patient’s overall health, the presence of tumours, the patient’s preoperative liver function, and the potential for residual liver parenchymal. Anatomic resection (subsegmentectomy, segmentectomy, and lobectomy) and no anatomic resection were both performed during hepatectomy procedures. The whole tumours that had entered the bile duct were removed, and if necessary, a biliary-enteric anastomosis was carried out. By doing a paraffin pathological study on the specimen, every case was eventually and conclusively diagnosed [10].


Currently, surgery, chemotherapy, and immunotherapy are the main liver cancer treatment options. Since patients with advanced liver cancer still have a poor prognosis, it is critical to identify more accurate molecular diagnostic and therapeutic indicators for liver cancer. Discovered that can facilitate the spread of gastric cancer to the peritoneum and may be therapeutic target for the disease. Another study hypothesised that the presence of Mir- 638 in serum exosomes could be a significant and independent hepatocellular cancer prognostic factor. It was discovered that expression of CMTM6 and PD-L1 was related to immune microenvironment activation and a good prognosis for colorectal cancer. These results offer solid support for our understanding of the immunological mechanism and prognosis of liver cancer, although our research on these topics is still lacking [11].

The results of our investigation, which is the first to examine PPM1G expression in liver cancer, show that the expression of the PPM1G gene and protein in patients with liver cancer is lower than that in healthy surrounding tissues. But Ding et alresearch’s runs counter to what we discovered. Their findings imply that PPM1G is substantially expressed in tissues from cervical carcinoma. We think that the heterogeneity of various cancers may be the cause of the varying PPM1G expression in various malignancies. Additionally, we discovered that individuals with liver cancer who had high PPM1G expression had a good prognosis while those with gastric cancer who had high PPM1G expression had a poor prognosis. We think there are two explanations for this: one, there weren’t enough patients included in the study, and second, other factors might have an impact on how well tumour patient’s fare [12].


The results of the present investigation suggest that BDI was related with a more advanced tumour stage and that central BDI was an independent risk factor affecting the prognosis of patients with HCC, despite the limitations of a retrospective study. The only chance for patients’ long-term survival is curative surgery that involves the total removal of tumours and infected bile ducts.

The usefulness of this strategy was demonstrated by the implementation of NMFBFS on a clinical dataset of HCC. Many well-known symptoms of HCC patients were present in the ideal clinical features that the NMFBFS technique produced. This paper also offers a generic computational foundation for a novel feature selection method that is effective in locating the best feature subset from a high-dimensional dataset.



Conflicts of Interest



  1. Kim SH, Turnbull J, Guimond S  et al. Extracellular matrix and cell signalling the dynamic cooperation of integrin proteoglycan an growth factor receptor. Journal of Endocrinology. 209,139-151 (2011).
  2. Google Scholar, Crossref, Indexed at

  3. Heldin P, Basu K, Kozlova I et al. HAS2 and CD44 in breast tumorigenesis. Advances in Cancer Research. 123,211-229 (2014).
  4. Google Scholar     Crossref, Indexed at

  5. Chua SS, Chan SP. Medication adherence and achievement of glycaemic targets in ambulatory type 2 diabetic patients. Journal of Applied Pharmaceutical Science. 1, 55-59 (2011).
  6. Google Scholar, Crossref, Indexed at

  7. Ahren B et al. DPP-4 inhibitors Best Practice and Research in Clinical Endocrinology. Metabolism. 21,517-533 (2007).
  8. Google Scholar, Crossref, Indexed at

  9. Shimizu Y, Tada Y, Yamauchi M et al. Hypophosphatemia induced by intravenous administration of saccharides ferric oxide. Bone. 45,814-816 (2009).
  10. Google Scholar, Crossref, Indexed at

  11. Bosch FX, Ribes J, Cléries R et al. Epidemiology of hepatocellular carcinoma. Clinics in Liver Disease. 9,191-211 (2005).
  12. Google Scholar, Crossref, Indexed at

  13. Miller G, Schwartz LH, Angelica MD et al. (2007) the use of Imaging in the diagnosis and staging of hepatobiliary malignancies. Surgical Oncology Clinics of North America. 16,343-368 (2007).
  14. Google Scholar, Crossref, Indexed at

  15. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. Journal of Herpetology 41,864-880 (2004).
  16. Google Scholar, Crossref, Indexed at

  17. Mineno J, Okamoto S, Ando T et al. The expression profile of microRNAs in mouse embryos. Nucleic Acids Research. 34, 1765-1771 (2006).
  18. Google Scholar, Crossref, Indexed at

  19. Yamagata K, Fujiyama S, Ito S et al. Maturation of microRNA is hormonally regulated by a nuclear receptor. Molecular Cell. 36,340-347 (2009).
  20. Google Scholar, Crossref, Indexed at

  21. Liu WH, Yeh SH, Chen PJ et al. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta. 1809, 678-685 (2011).
  22. Google Scholar, Crossref, Indexed at

  23. Hu H, Wang CJ, Gong L et al. (2007) Expression and significance of apoptosis inhibitor living in hepatocellular carcinoma. Chinese Journal of Hepatobiliary Surgery. 13,348 (2007).
  24. Google Scholar, Crossref, Indexed at